Jul 7, 2023

Could regenerating the thymus boost human longevity?

Posted by in categories: biotech/medical, life extension

DISCLOSURE: Longevity. Technology (a brand of First Longevity Limited) has been contracted by the company featured in this article to support its current funding round. Qualifying investors can find out more via the Longevity. Technology investor portal.

British regenerative medicine company Videregen is on a mission to cure chronic diseases and is targeting the human immune system through its work to regenerate the thymus. Building on groundbreaking work conducted at the Francis Crick Institute, Videregen believes its technology holds the potential to restore the function of the aging immune system. The company is already approved for initial clinical trials of its technology in respiratory disease and is working towards trials of its regenerative thymus technology within three years.

Longevity Technology: The thymus is a small but important organ in the immune system and is responsible for the development and maturation of critical T cells. It plays a key role in our early development, but declines significantly as we age, along with the functionality of our immune system, and its decline is linked to several age-related and chronic diseases. Videregen is betting that its technology can help restore the thymus, potentially rejuvenating our immune system in the process. To learn more, we spoke to the company’s CEO, Dr Steve Bloor.

Leave a reply